Top-Rated Stocks NASDAQ:NTLA Intellia Therapeutics - NTLA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $43.85 +0.62 (+1.43%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$42.41▼$44.2450-Day Range$33.21▼$51.4652-Week Range$32.44▼$104.87Volume745,755 shsAverage Volume1.17 million shsMarket Capitalization$3.45 billionP/E RatioN/ADividend YieldN/APrice Target$100.16 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Intellia Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside128.4% Upside$100.16 Price TargetShort InterestBearish8.34% of Shares Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.71Based on 10 Articles This WeekInsider TradingSelling Shares$431,934 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.11) to ($5.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.69 out of 5 starsMedical Sector84th out of 1,027 stocksDiagnostic Substances Industry3rd out of 15 stocks 4.4 Analyst's Opinion Consensus RatingIntellia Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $100.16, Intellia Therapeutics has a forecasted upside of 128.4% from its current price of $43.85.Amount of Analyst CoverageIntellia Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.34% of the outstanding shares of Intellia Therapeutics have been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Intellia Therapeutics has recently decreased by 1.06%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntellia Therapeutics has received a 74.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for genetic diseases", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Intellia Therapeutics is -0.67. Previous Next 3.2 News and Social Media Coverage News SentimentIntellia Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Intellia Therapeutics this week, compared to 2 articles on an average week.Search Interest27 people have searched for NTLA on MarketBeat in the last 30 days. This is an increase of 42% compared to the previous 30 days.MarketBeat FollowsOnly 17 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -6% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $431,934.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions85.61% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intellia Therapeutics are expected to grow in the coming year, from ($6.11) to ($5.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intellia Therapeutics is -7.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intellia Therapeutics is -7.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Intellia Therapeutics (NASDAQ:NTLA) StockIntellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.Read More Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Stock News HeadlinesFebruary 7, 2023 | americanbankingnews.comAnalysts Offer Predictions for Intellia Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:NTLA)February 6, 2023 | finance.yahoo.comWall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here's is How to TradeFebruary 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...February 3, 2023 | americanbankingnews.comCantor Fitzgerald Begins Coverage on Intellia Therapeutics (NASDAQ:NTLA)February 1, 2023 | finance.yahoo.comDoes Intellia Therapeutics Stock Have Good Genes?January 27, 2023 | nasdaq.comBlackRock Inc. Increases Position in Intellia Therapeutics Inc (NTLA)January 7, 2023 | markets.businessinsider.comZM, NTLA, or SQ: Which Cathie Wood’s ARKK ETF Stock Seems More Appealing in 2023?January 5, 2023 | finance.yahoo.comIntellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key MilestonesFebruary 7, 2023 | Investing Trends (Ad)New "Vertical" Technology Solves Solar Power's Major FlawEven conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.December 19, 2022 | forbes.comWill Intellia Therapeutics Stock Rebound After A 31% Fall In A Month?December 5, 2022 | seekingalpha.comVerve drops 21% as FDA seeks more data to lift clinical hold on lead assetDecember 1, 2022 | finanznachrichten.deIntellia Therapeutics, Inc.: Intellia Therapeutics Announces Pricing of Public Offering of Common StockNovember 15, 2022 | markets.businessinsider.comIntellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%November 14, 2022 | finance.yahoo.comIntellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack RatesNovember 12, 2022 | finance.yahoo.comIntellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific MeetingNovember 7, 2022 | thestreet.comVerve Therapeutics Crushed By Clinical HoldNovember 7, 2022 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Intellia Therapeutics (NTLA)November 4, 2022 | nasdaq.comIntellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/YNovember 3, 2022 | finance.yahoo.comUltragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/YNovember 2, 2022 | msn.comEarnings Preview For Intellia TherapeuticsNovember 2, 2022 | finance.yahoo.comRepligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 GuidanceOctober 27, 2022 | technews.tmcnet.comIntellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company UpdatesOctober 14, 2022 | finance.yahoo.com10 Best Gene Editing Stocks To BuyOctober 11, 2022 | uk.investing.comIntellia Therapeutics Inc (38I)October 8, 2022 | nasdaq.comIntellia Therapeutics Inc Shares Close the Day 10.6% Lower - Daily WrapOctober 7, 2022 | finance.yahoo.com‘Take Opportunities on Days Like Today’: Mary Callahan Erdoes Says Now Could Be the Best Time to Invest. Here Are 3 Stocks to ConsiderSeptember 20, 2022 | finance.yahoo.comCathie Wood Is Loading Up on These 3 Stocks: Should You?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Company Calendar Last Earnings11/04/2021Today2/06/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTLA CUSIPN/A CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees485Year FoundedN/APrice Target and Rating Average Stock Price Forecast$100.16 High Stock Price Forecast$180.00 Low Stock Price Forecast$39.00 Forecasted Upside/Downside+128.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($5.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-267,890,000.00 Net Margins-859.92% Pretax Margin-859.92% Return on Equity-47.79% Return on Assets-37.68% Debt Debt-to-Equity RatioN/A Current Ratio6.55 Quick Ratio6.55 Sales & Book Value Annual Sales$33.05 million Price / Sales104.39 Cash FlowN/A Price / Cash FlowN/A Book Value$14.15 per share Price / Book3.10Miscellaneous Outstanding Shares78,680,000Free Float76,638,000Market Cap$3.45 billion OptionableOptionable Beta1.90 Key ExecutivesJohn M. LeonardPresident, Chief Executive Officer & DirectorGlenn GoddardTreasurer, Chief Financial & Accounting OfficerLaura Sepp-LorenzinoChief Scientific Officer & Executive VPDavid LebwohlChief Medical Officer & Executive Vice PresidentEliana ClarkChief Technology Officer & Executive VPKey CompetitorsLantheusNASDAQ:LNTHNeogenNASDAQ:NEOGCelldex TherapeuticsNASDAQ:CLDXMyriad GeneticsNASDAQ:MYGNMeridian BioscienceNASDAQ:VIVOView All CompetitorsInsiders & InstitutionsBanque Pictet & Cie SASold 83,382 shares on 2/6/2023Ownership: 0.029%Los Angeles Capital Management LLCSold 1,280 shares on 2/6/2023Ownership: 0.014%Privium Fund Management B.V.Bought 2,000 shares on 2/3/2023Ownership: 0.009%ProShare Advisors LLCBought 2,819 shares on 2/2/2023Ownership: 0.024%Profund Advisors LLCBought 1,458 shares on 2/2/2023Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions NTLA Stock - Frequently Asked Questions Should I buy or sell Intellia Therapeutics stock right now? 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTLA shares. View NTLA analyst ratings or view top-rated stocks. What is Intellia Therapeutics' stock price forecast for 2023? 18 brokerages have issued 1-year target prices for Intellia Therapeutics' shares. Their NTLA share price forecasts range from $39.00 to $180.00. On average, they expect the company's share price to reach $100.16 in the next year. This suggests a possible upside of 128.4% from the stock's current price. View analysts price targets for NTLA or view top-rated stocks among Wall Street analysts. How have NTLA shares performed in 2023? Intellia Therapeutics' stock was trading at $34.89 at the start of the year. Since then, NTLA stock has increased by 25.7% and is now trading at $43.85. View the best growth stocks for 2023 here. When is Intellia Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our NTLA earnings forecast. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) posted its earnings results on Thursday, November, 4th. The company reported ($0.97) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by $0.12. The firm earned $7.20 million during the quarter, compared to analyst estimates of $8.66 million. Intellia Therapeutics had a negative net margin of 859.92% and a negative trailing twelve-month return on equity of 47.79%. Intellia Therapeutics's revenue for the quarter was down 67.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.47) earnings per share. What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO? 12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO). When did Intellia Therapeutics IPO? (NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Intellia Therapeutics' stock symbol? Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA." Who are Intellia Therapeutics' major shareholders? Intellia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.97%), Sumitomo Mitsui Trust Holdings Inc. (3.78%), Capital Advisors Inc. OK (0.22%), Gratus Capital LLC (0.09%), New York State Common Retirement Fund (0.08%) and State of New Jersey Common Pension Fund D (0.06%). Insiders that own company stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Intellia Therapeutics' stock price today? One share of NTLA stock can currently be purchased for approximately $43.85. How much money does Intellia Therapeutics make? Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $3.45 billion and generates $33.05 million in revenue each year. The company earns $-267,890,000.00 in net income (profit) each year or ($5.87) on an earnings per share basis. How many employees does Intellia Therapeutics have? The company employs 485 workers across the globe. How can I contact Intellia Therapeutics? Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com. This page (NASDAQ:NTLA) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.